/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) ( 10 2 %) (g/l) ( 10 2 %) 0.75 ( 10 2 %) 0.15 ( 10 2 %)
|
|
- なおちか さわい
- 5 years ago
- Views:
Transcription
1 / B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) (10 2 %) (10 2 %) 0.75 (10 2 %) 0.15 (10 2 %) % % % 0.10 Bands(10 2 %) 0.10 ( ( (mmol BUN/Urea (mmol Ca (mmol Cl mmol (µmol (mmol (mmol LDH 750 mmol (mmol SGOT/ASAT SGPT/ALAT (µmol (µmol
2 -299 (N=1337) (N=1148) (N=817) 66 (4.9) 835 (62.5) 901 (67.4) 38 (3.3) 736 (64.1) 774 (67.4) 33 (4.0) 531 (65.0) 4 (69.0) 40 (3.1) 693 (51.8) 733 (54.8) 20 (1.7) 596 (51.9) 616 (53.7) 15 (1.8) 453 (55.4) 468 (57.3) 1 (<1) 17 (1.3) 18 (1.3) 0 16 (1.4) 16 (1.4) 0 12 (1.5) 12 (1.5) 1 (<1) 0 1 (<1) 0 1 (<1) 1 (<1) (1.9) 272 (20.3) 297 (22.2) 12 (1.0) 210 (18.3) 222 (19.3) 13 (1.6) 225 (27.5) 238 (29.1) 1 (<1) 2 (<1) 3 (<1) 2 (<1) 1 (<1) 3 (<1) 0 4 (<1) 4 (<1) 22 (1.6) 246 (18.4) 268 (20.0) 13 (1.1) 214 (18.6) 227 (19.8) 12 (1.5) 151 (18.5) 163 (20.0) BUN 16 (1.2) 63 (4.7) 79 (5.9) 6 (<1) 53 (4.6) 59 (5.1) 9 (1.1) 48 (5.9) 57 (7.0) /UREA (<1) 1 (<1) 0 2 (<1) 2 (<1) 0 2 (<1) 2 (<1) (<1) 27 (2.0) 31 (2.3) 2 (<1) 21 (1.8) 23 (2.0) 0 25 (3.1) 25 (3.1) 15 (1.1) 242 (18.1) 257 (19.2) 12 (1.0) 209 (18.2) 221 (19.2) 9 (1.1) 133 (16.3) 142 (17.4) 0 2 (<1) 2 (<1) 0 2 (<1) 2 (<1) (<1) 16 (1.2) 18 (1.3) 1 (<1) 14 (1.2) 15 (1.3) 2 (<1) 7 (<1) 9 (1.1) K 0 9 (<1) 9 (<1) 0 7 (<1) 7 (<1) 0 3 (<1) 3 (<1) SGOT 5 (<1) 18 (1.3) 23 (1.7) 5 (<1) 15 (1.3) 20 (1.7) 5 (<1) 13 (1.6) 18 (2.2) /ASAT SGPT 3 (<1) 14 (1.0) 17 (1.3) 3 (<1) 9 (<1) 12 (1.0) 3 (<1) 12 (1.5) 15 (1.8) /ALAT 10 (<1) 25 (1.9) 35 (2.6) 8 (<1) 23 (2.0) 31 (2.7) 6 (<1) 21 (2.6) 27 (3.3) 34 (2.5) 169 (12.6) 203 (15.1) 17 (1.5) 143 (12.5) 160 (13.9) 19 (2.3) 101 (12.4) 120 (14.7) LDH 3 (<1) 17 (1.3) 20 (1.5) 3 (<1) 17 (1.5) 20 (1.7) 2 (<1) 19 (2.3) 21 (2.6) ( ) : 1: 7: :
3 0 16 (51.6) 16 (51.6) 0 16 (29.1) 16 (29.1) (28.6) 0 5 (16.1) 5 (16.1) 0 2 (3.6) 2 (3.6) 0 4 (7.1) 4 (7.1) / Part ( -300) ICU ( ) Part Part (N=31) (N=55) (N=) 0 23 (74.2) 23 (74.2) 0 38 (69.1) 38 (69.1) 0 32 (57.1) 32 (57.1) 0 20 (64.5) 20 (64.5) 0 29 (52.7) 29 (52.7) 0 29 (51.8) 29 (51.8) 0 17 (54.8) 17 (54.8) 0 24 (43.6) 24 (43.6) 0 21 (37.5) 21 (37.5) 0 10 (32.3) 10 (32.3) 0 15 (27.3) 15 (27.3) 0 17 (30.4) 17 (30.4) Ca 0 3 (9.7) 3 (9.7) 0 7 (12.7) 7 (12.7) 0 7 (12.5) 7 (12.5) 0 2 (6.5) 2 (6.5) (3.6) 2 (3.6) (22.6) 7 (22.6) 0 25 (45.6) 25 (45.6) 0 15 (26.8) 15 (26.8) 0 1 (3.2) 1 (3.2) 0 2 (3.6) 2 (3.6) 0 2 (3.6) 2 (3.6) (1.8) 1 (1.8) (3.2) 1 (3.2) 0 2 (3.6) 2 (3.6) 0 1 (1.8) 1 (1.8) SGOT/ASAT 0 1 (3.2) 1 (3.2) 0 5 (9.0) 5 (9.0) 0 4 (7.1) 4 (7.1) SGPT/ALAT 0 1 (3.2) 1 (3.2) 0 2 (3.6) 2 (3.6) 0 2 (3.6) 2 (3.6) Na (1.8) 1 (1.8) (5.5) 3 (5.5) 0 1 (1.8) 1 (1.8) ( ) : 1: 7: : Part Part (N=12) (N=6) (N=6) 10 (83.3) 0 10 (83.3) 5 (83.3) 0 5 (83.3) 5 (83.3) 0 5 (83.3) 7 (58.3) 1 (8.3) 8 (66.7) 5 (83.3) 0 5 (83.3) 5 (83.3) 0 5 (83.3) 2 (16.7) 0 2 (16.7) 3 (50.0) 0 3 (50.0) 4 (66.7) 0 4 (66.7) 4 (33.3) 0 4 (33.3) 0 4 (66.7) 4 (66.7) (50.0) 1 (8.3) 0 1 (8.3) (8.3) 5 (41.6) 6 (50.0) 1 (16.7) 0 1 (16.7) 2 (33.3) 0 2 (33.3) 5 (41.6) 0 5 (41.6) 2 (33.3) 0 2 (33.3) 4 (66.7) 0 4 (66.7) 0 4 (33.3) 4 (33.3) BUN/Urea 6 (50.0) 0 6 (50.0) 2 (33.3) 0 2 (33.3) 4 (66.7) 0 4 (66.7) 1 (8.3) 0 1 (8.3) (16.7) 0 1 (16.7) 0 1 (8.3) 1 (8.3) ( ) : 1: 7: :
4 Part Part (N=85) (N=178) (N=175) 11 (12.9) 62 (72.9) 73 (85.9) 15 (8.4) 145 (81.5) 160 (89.9) 11 (6.3) 144 (82.3) 155 (88.6) 9 (10.6) 58 (68.2) 67 (78.8) 7 (3.9) 127 (71.3) 134 (75.2) 5 (2.9) 143 (81.7) 148 (84.6) 0 2 (2.4) 2 (2.4) 0 7 (3.9) 7 (3.9) 0 6 (3.4) 6 (3.4) 1 (1.2) 0 1 (1.2) (9.4) 41 (48.2) 51 (60.0) 3 (1.7) 101 (.7) 104 (58.4) 5 (2.9) (69.1) 1 (1.2) 0 1 (1.2) 1 (0.6) 1 (0.6) 2 (1.1) 0 2 (1.1) 2 (1.19) 4 (4.7) 20 (23.5) 24 (28.2) 8 (4.5) 46 (25.8) 54 (30.3) 5 (2.9) 46 (26.3) 51 (29.1) (0.6) 0 1 (0.6) (0.6) 1 (0.6) 15 (17.6) 40 (47.1) 55 (64.7) 14 (7.9) 109 (61.2) 123 (69.1) 14 (8.0) 106 (60.6) 120 (68.6) AL-P 1 (1.2) 0 1 (1.2) 0 3 (1.7) 3 (1.7) 0 1 (0.6) 1 (0.6) BUN/UREA 3 (3.5) 4 (4.7) 8 (9.4) 1 (0.6) 22 (12.4) 23 (12.9) 2 (1.1) 24 (13.7) 26 (14.9) 0 1 (1.2) 1 (1.2) (0.6) 1 (0.6) Ca 26 (30.6) 53 (62.4) 79 (92.9) 50 (28.1) 116 (65.2) 166 (93.3) 37 (21.1) 123 (70.3) 160 (91.4) (1.1) 2 (1.1) Cl 1 (1.2) 1 (1.2) 2 (2.4) 4 (2.2) 0 3 (1.7) (5.9) 5 (5.9) 0 7 (3.9) 7 (3.9) 0 14 (8.0) 14 (8.0) 1 (1.2) 27 (31.8) 28 (32.9) 7 (3.9) 47 (26.4) 54 (30.3) 4 (2.3) 50 (28.6) 54 (30.9) 1 (1.2) 0 1 (1.2) 1 (0.6) 9 (5.1) 10 (5.6) 1 (0.6) 7 (4.0) 8 (4.6) 1 (1.2) 1 (1.2) 2 (2.4) 2 (1.1) 7 (3.9) 9 (5.1) 2 (1.1) 5 (2.9) 7 (4.0) (1.7) 3 (1.7) 1 (0.6) 1 (0.6) 2 (1.1) K 0 1 (1.2) 1 (1.2) 0 4 (2.2) 4 (2.2) SGOT/ASAT 0 4 (4.7) 4 (4.7) 1 (0.6) 9 (5.1) 10 (5.6) 2 (1.1) 5 (2.9) 7 (4.0) SGPT/ALAT 0 4 (4.7) 4 (4.7) 1 (0.6) 5 (2.8) 6 (3.4) 1 (0.6) 6 (3.4) 7 (4.0) 1 (1.2) 3 (3.5) 4 (4.7) 1 (0.6) 10 (5.6) 11 (6.2) 4 (2.3) 5 (2.9) 9 (5.1) 12 (14.1) 33 (38.8) 45 (52.9) 12 (6.7) 96 (53.9) 108 (60.7) 12 (6.9) 87 (49.7) 99 (.6) Na (1.1) 2 (1.1) (0.6) 1 (0.6) 2 (1.1) 1 (0.6) 4 (2.3) 5 (2.9) ( ) : 1: 7: : Part Part (N=92) (N=203) (N=198) 7 (7.6) 65 (70.7) 72 (78.3) 18 (8.9) 149 (73.4) 167 (82.3) 17 (8.6) 159 (80.3) 176 (88.9) 4 (4.3) 60 (65.2) 64 (69.6) 8 (3.9) 137 (67.5) 145 (71.4) 5 (2.5) 142 (71.7) 147 (74.2) (0.5) 1 (0.5) 1 (1.1) 2 (2.2) 3 (3.3) 0 3 (1.5) 3 (1.5) 0 5 (2.5) 5 (2.5) 3 (3.3) 47 (51.1) 50 (54) 6 (3.0) 102 (50.2) 108 (53.2) 4 (2.0) 114 (57.6) 118 (59.6) 0 1 (1.1) 1 (1.1) 1 (0.5) 4 (2.0) 5 (2.5) 0 5 (2.5) 5 (2.5) 1 (1.1) 23 (25.0) 24 (26.1) 4 (2.0) 63 (31.0) 67 (33.0) 4 (2.0) 42 (21.2) 46 (23.2) (0.5) 0 1 (0.5) (1.1) 0 1 (1.1) (0.5) 0 1 (0.5) 3 (3.3) 41 (45) 44 (48) 6 (3.0) 114 (.2) 120 (59.1) 10 (5.1) 108 (54.5) 118 (59.6) Al-P 0 (0 1 (1.1) 1 (1.1) BUN/UREA 1 (1.1) 5 (5.4) 6 (6.5) 2 (1.0) 13 (6.4) 15 (7.4) 2 (1.0) 15 (7.6) 17 (8.6) 0 (0 0 ( (0.5) 1 (0.5) 0 1 (0.5) 1 (0.5) Ca 21 (22.8) 61 (66.3) 82 (89.1) 59 (29.1) 127 (62.6) 186 (91.6) 49 (24.7) 142 (71.7) 191 (96.5) (0.5) 1 (0.5) Cl 0 3 (3.3) 3 (3.3) 2 (1.0) 6 (3.0) 8 (3.9) 1 (0.5) 2 (1.0) 3 (1.5) 1 (1.1) 2 (2.2) 3 (3.3) 1 (0.5) 2 (1.0) 3 (1.5) 0 8 (4.0) 8 (4.0) 2 (2.2) 33 (35.9) 35 (38.0) 4 (2.0) 64 (31.5) 68 (33.5) 4 (2.0) 59 (29.8) 63 (31.8) 3 (3.3) 8 (8.7) 11 (12.0) 4 (2.0) 11 (5.4) 15 (7.4) 5 (2.5) 16 (8.1) 21 (10.6) 2 (2.2) 1 (1.1) 3 (3.3) 0 7 (3.4) 7 (3.4) 3 (1.5) 5 (2.5) 8 (4.0) 1 (1.1) 1 (1.1) 2 (2.2) 1 (0.5) 4 (2.0) 5 (2.5) 1 (0.5) 4 (2.0) 5 (2.5) K 0 2 (2.2) 2 (2.2) (0) 2 (1.0) 2 (1.0) SGOT/ASAT 0 3 (3.3) 3 (3.3) 2 (1.0) 5 (2.5) 7 (3.4) 2 (1.0) 3 (1.5) 5 (2.5) SGPT/ALAT 0 3 (3.3) 2 (2.2) 1 (0.5) 1 (0.5) 2 (1.0) 0 1 (0.5) 1 (0.5) Na (0.5) 1 (0.5) 0 1 (0.5) 1 (0.5) 1 (1.1) 5 (5.4) 6 (6.5) 6 (3.0) 7 (3.4) 13 (6.4) 2 (1.0) 13 (6.6) 15 (7.6) 5 (5.4) 36 (39.1) 41 (44.6) 4 (2.0) 94 (46.3) 98 (48.3) 7 (3.5) 90 (45.5) 97 (49.0) 1 (1.1) 0 1 (1.1) 1 (0.5) 1 (0.5) 2 (1.0) 0 (0) 2 (1.0) 2 (1.0) ( ) : 1: 7: :
5 B ( -304) CABG 61% RBC VL N=148 N= (1.4) 0 2 (1.4) 95 (64.2) 43 (29.1) 138 (93.2) 91 (61.6) 40 (27.2) 131 (89.1) 70 (47.3) 51 (34.5) 121 (81.8) 65 (44.2) 51 (34.7) 116 (78.9) (0.7) 1 (0.7) 2 (1.4) 3 (2.0) 5 (3.4) 5 (3.4) 1 (0.7) 6 (4.1) RBC 49 (33.1) 46 (31.1) 95 (64.2) (38.1) 35 (23.8) 91 (61.9) 1 (0.7) 1 (0.7) 2 (1.4) 0 1 (0.7) 1 (0.7) WBC 28 (18.9) 13 (8.8) 41 (27.7) 22 (15.0) 12 (8.2) 34 (23.1) 30 (20.3) 22 (14.9) 52 (35) 21 (14.3) 20 (13.6) 41 (27.9) Al-P (0.7) 0 1 (0.7) BUN/Urea 6 (4.1) 5 (3.4) 11 (7.4) 13 (8.8) 8 (5.4) 21 (14.3) 77 (52.0) 32 (21.6) 109 (73.6) 80 (54.4) 32 (21.8) 112 (76.2) (0.7) 0 1 (0.7) 1 (0.7) 4 (2.7) 5 (3.4) 0 2 (1.4) 2 (1.4) GGT 14 (9.5) 3 (2.0) 17 (11.5) 7 (4.8) 1 (0.7) 8 (5.4) (0.7) 0 1 (0.7) 17 (11.5) 20 (13.5) 37 (25.0) 23 (15.6) 16 (10.9) 39 (26.5) 5 (3.4) 7 (4.7) 12 (8.1) 6 (4.1) 9 (6.1) 15 (10.2) 2 (1.4) 0 2 (1.4) LDH 0 2 (1.4) 2 (1.4) 1 (0.7) 1 (0.7) 2 (1.4) (0.7) 0 1 (0.7) 0 2 (1.4) 2 (1.4) SGOT/ASAT 2 (1.4) 3 (2.0) 5 (3.4) 1 (0.7) 2 (1.4) 3 (2.0) SGPT/ALAT (0.7) 1 (0.7) 2 (1.4) 3 (2.0) 1 (0.7) 4 (2.7) 1 (0.7) 0 1 (0.7) 14 (9.5) 9 (6.1) 23 (15.5) 11 8 (5.4) 19 (12.9) 1 (0.7) 0 1 (0.7) 0 2 (1.4) 2 (1.4) ( ) : 1: 7: :
6 1 (1.6) 1 (1.6) 2 (3.2) 3 (2.3) 0 3 (2.3) B ( -305) (Loading 6.0g/kg/hr 10 ) (Loading 3.0g/kg/hr 20 ) (6.0g/kg/hr) (N=62) (3.0g/kg/hr) (N=130) 21 (33.9) 33 (53.2) 54 (87.1) 46 (35.4) 65 (50.0) 111 (85.4) (0.8) 1 (0.8) 5 (8.1) 26 (41.9) 31 (50.0) 19 (14.6) 61 (46.9) 80 (61.5) (0.8) 1 (0.8) (0.8) 1 (0.8) 3 (4.8) 21 (33.9) 24 (38.7) 16 (12.3) 47 (36.2) 63 (48.5) (0.8) 1 (0.8) 3 (4.8) 13 (21.0) 16 (25.8) 6 (4.6) 29 (22.3) 35 (26.9) 1 (1.6) 11 (17.7) 12 (19.4) 1 (0.8) 21 (16.2) 22 (16.9) 8 (12.9) 20 (32.3) 28 (45.2) 13 (10.0) 46 (35.4) 59 (45.4) (0.8) 1 (0.8) BUN/UREA 0 3 (4.8) 3 (4.8) 2 (1.5) 12 (9.2) 14 (10.8) 30 (48.4) 27 (43.5) 57 (91.9) 60 (46.2) 47 (36.2) 107 (82.3) Cl 0 1 (1.6) 1 (1.6) 2 (1.5) 0 2 (1.5) 0 1 (1.6) 1 (1.6) 0 1 (0.8) 1 (0.8) -GTP 4 (6.5) 3 (4.8) 7 (11.3) 9 (6.9) 8 (6.2) 17 (13.1) (0.8) 1 (0.8) 2 (3.2) 9 (14.5) 11 (17.7) 4 (3.1) 22 (16.9) 26 (20.0) 2 (3.2) 0 2 (3.2) 1 (0.8) 2 (1.5) 3 (2.3) 0 1 (1.6) 1 (1.6) 1 (0.8) 1 (0.8) 2 (1.5) LDH 0 2 (3.2) 2 (3.2) 0 1 (0.8) 1 (0.8) 1 (1.6) 0 1 (1.6) 1 (0.8) 1 (0.8) 2 (1.5) (0.8) 1 (0.8) 2 (1.5) SGOT/ASAT 1 (1.6) 4 (6.5) 5 (8.1) 0 2 (1.5) 2 (1.5) SGPT/ALAT 0 3 (4.8) 3 (4.8) 2 (1.5) 4 (3.1) 6 (4.6) (1.5) 2 (1.5) 0 1 (1.6) 1 (1.6) 0 1 (0.8) 1 (0.8) 0 2 (3.2) 2 (3.2) 0 4 (3.1) 4 (3.1) (0.8) 1 (0.8) 2 (1.5) ( ) : 1: 7: :
7 g/kg g/kg 0.1g/kg 1 24 PT APTT g/kg 0.3g/kg /L N=3 0.3 /L N=3 0.6 /L N=3 1(33.3) 0 1(33.3) 0 1(33.3) 0 1(33.3) 0 3(100.0) (66.6) 0 3(100.0) 0 1(33.3) (33.3) (66.6) 0 1(33.3) (66.6) 0 0 1(33.3) PT 1(33.3) 1(33.3) 2(66.6) 0 2(66.6) 0 APTT 0 2(66.6) 0 1(33.3) 0 1(33.3) Al-P (33.3) 0 1(33.3) 1(33.3) 0 1(33.3) 0 0 1(33.3) 1(33.3) (66.6) 0 A/G (33.3) (33.3) (66.6) 0 2(66.6) 0 1(33.3) 1(33.3) 0 1(33.3) 0 1(33.3) 0 K 1(33.3) (33.3) 0 SGOT/ASAT 0 0 1(33.3) SGPT/ALAT 0 1(33.3) (33.3) LDH 0 0 2(66.6) 0 2(66.6) 0 1(33.3) (33.3) (33.3) BUN (33.3) 0 0 Fe (66.6) 0 0 1(33.3) 0 2(66.6) 0 3(100.0) 0 1(33.3) 0 1(33.3) (33.3)
8 589 (N=30) 0.2g/kg (N=31) 0.4g/kg (N=28) 0.6g/kg (N=25) 0.8g/kg (N=25) 287/ / / / / (46.7) 14 (46.7) 3 (9.7) 15 (48.4) 18 (58.1) 1 (3.6) 10 (35.7) 11 (39.3) 0 15 (60.0) 15 (60.0) 0 12 (48.0) 12 (48.0) 0 13 (43.3) 13 (43.3) 2 (6.5) 10 (32.3) 12 (38.7) 0 13 (46.4) 13 (46.4) 0 11 (44.0) 11 (44.0) 0 10 (40.0) 10 (40.0) 0 2 (6.7) 2 (6.7) 0 4 (12.9) 4 (12.9) 0 4 (14.3) 4 (14.3) 0 5 (20.0) 5 (20.0) 0 1 (4.0) 1 (4.0) 1 (3.3) 11 (36.7) 12 (40.0) 1 (3.2) 6 (19.4) 7 (22.6) 1 (3.6) 11 (39.3) 12 (42.9) 0 12 (48.0) 12 (48.0) 0 7 (28.0) 7 (28.0) 0 1 (3.3) 1 (3.3) (4.0) 1 (4.0) (16.7) 5 (16.7) 1 (3.2) 5 (16.1) 6 (19.4) 0 4 (14.3) 4 (14.3) 0 8 (32.0) 8 (32.0) 0 3 (12.0) 3 (12.0) 2 (6.7) 13 (43.3) 15 (50.0) 4 (12.9) 7 (22.6) 11 (35.5) 3 (10.7) 11 (39.3) 14 (50.0) 0 11 (44.0) 11 (44.0) 0 7 (28.0) 7 (28.0) 0 14 (46.7) 14 (46.7) 3 (9.7) 15 (48.4) 18 (58.1) 2 (7.1) 9 (32.1) 11 (39.3) 0 13 (52.0) 13 (52.0) 0 12 (48.0) 12 (48.0) 0 13 (43.3) 13 (43.3) 2 (6.5) 15 (48.4) 17 (54.8) 2 (7.1) 11 (39.3) 13 (46.4) 0 16 (64.0) 16 (64.0) 0 14 (.0) 14 (.0) 0 5 (16.7) 5 (16.7) 1 (3.2) 6 (19.4) 7 (22.6) 0 2 (7.1) 2 (7.1) 0 3 (12.0) 3 (12.0) 0 1 (4.0) 1 (4.0) 0 6 (20.0) 6 (20.0) 2 (6.5) 11 (35.5) 13 (41.9) 1 (3.6) 8 (28.6) 9 (32.1) 0 15 (60.0) 15 (60.0) 0 11 (44.0) 11 (44.0) 0 9 (30.0) 9 (30.0) 4 (12.9) 4 (12.9) 8 (25.8) 1 (3.6) 6 (21.4) 7 (25.0) 0 9 (36.0) 9 (36.0) 0 5 (20.0) 5 (20.0) 0 2 (6.7) 2 (6.7) 5 (16.1) 3 (9.7) 8 (25.8) 1 (3.6) 0 1 (3.6) 0 3 (12.0) 3 (12.0) 0 2 (8.0) 2 (8.0) 1 (3.3) 21 (70.0) 22 (73.3) 2 (6.5) 22 (71.0) 24 (77.4) 0 17 (60.7) 17 (60.7) 0 20 (80.0) 20 (80.0) 0 14 (.0) 14 (.0) 1 (3.3) 19 (63.3) 20 (66.7) 4 (12.9) 19 (61.3) 23 (74.2) 3 (10.7) 17 (60.7) 20 (71.4) 0 18 (72.0) 18 (72.0) 0 17 (68.0) 17 (68.0) A/G 1 (3.3) 5 (16.7) 6 (20.0) 3 (9.7) 5 (16.1) 8 (25.8) 2 (7.1) 0 2 (7.1) (4.0) 1 (4.0) 1 (3.3) 14 (46.7) 15 (50.0) 4 (12.9) 14 (45.2) 18 (58.1) 1 (3.6) 6 (21.4) 7 (25.0) 0 12 (48.0) 12 (48.0) 0 9 (36.0) 9 (36.0) 0 8 (26.7) 8 (26.7) 1 (3.2) 4 (12.9) 5 (16.1) 1 (3.6) 7 (25.0) 8 (28.6) 0 9 (36.0) 9 (36.0) 0 6 (24.0) 6 (24.0) 0 6 (20.0) 6 (20.0) (3.6) 1 (3.6) 0 4 (16.0) 4 (16.0) 0 1 (4.0) 1 (4.0) 0 3 (10.0) 3 (10.0) 2 (6.5) 4 (12.9) 6 (19.4) 0 3 (10.7) 3 (10.7) 0 6 (24.0) 6 (24.0) 0 1 (4.0) 1 (4.0) SGOT/ASAT 2 (6.7) 9 (30.0) 11 (36.7) 3 (9.7) 5 (16.1) 8 (25.8) 4 (14.3) 1 (3.6) 5 (17.9) 0 6 (24.0) 6 (24.0) 1 (4.0) 1 (4.0) 2 (8.0) SGPT/ALAT 3 (10.0) 6 (20.0) 9 (30.0) 3 (9.7) 4 (12.9) 7 (22.6) 5 (17.9) 1 (3.6) 6 (21.4) 0 7 (28.0) 7 (28.0) 1 (4.0) 4 (16.0) 5 (20.0) -GTP 1 (3.3) 3 (10.0) 4 (13.3) 0 1 (3.2) 1 (3.2) 1 (3.6) 0 1 (3.6) 0 5 (20.0) 5 (20.0) 0 5 (20.0) 5 (20.0) LDH 0 2 (6.7) 2 (6.7) 1 (3.2) 4 (12.9) 5 (16.1) 2 (7.1) 3 (10.7) 5 (17.9) 0 6 (24.0) 6 (24.0) 0 1 (4.0) 1 (4.0) ALP 1 (3.3) 4 (13.3) 5 (16.7) 2 (6.5) 6 (19.4) 8 (25.8) 1 (3.6) 1 (3.6) 2 (7.1) 0 5 (20.0) 5 (20.0) 0 6 (24.0) 6 (24.0) CPK 1 (3.3) 15 (50.0) 16 (53.3) 2 (6.5) 14 (45.2) 16 (51.6) 3 (10.7) 14 (50.0) 17 (60.7) 0 17 (68.0) 17 (68.0) 0 18 (72.0) 18 (72.0) Na 0 2 (6.7) 2 (6.7) 0 1 (3.2) 1 (3.2) 1 (3.6) 1 (3.6) 2 (7.1) 0 3 (12.0) 3 (12.0) 0 5 (20.0) 5 (20.0) K 0 2 (6.7) 2 (6.7) 0 4 (12.9) 4 (12.9) 0 2 (7.1) 2 (7.1) 0 3 (12.0) 3 (12.0) 1 (4.0) 1 (4.0) 2 (8.0) Cl 0 1 (3.3) 1 (3.3) 0 1 (3.2) 1 (3.2) 1 (3.6) 5 (17.9) 6 (21.4) 0 2 (8.0) 2 (8.0) 0 6 (24.0) 6 (24.0) Ca 0 15 (50.0) 15 (50.0) 3 (9.7) 16 (51.6) 19 (61.3) 1 (3.6) 12 (42.9) 13 (46.4) 0 14 (.0) 14 (.0) 0 11 (44.0) 11 (44.0) P 0 3 (10.0) 3 (10.0) 1 (3.2) 4 (12.9) 5 (16.1) 1 (3.6) 5 (17.9) 6 (21.4) 0 7 (28.0) 7 (28.0) 0 6 (24.0) 6 (24.0) ph 0 2 (6.7) 2 (6.7) 0 2 (6.5) 2 (6.5) 0 1 (3.6) 1 (3.6) 0 2 (8.0) 2 (8.0) 0 1 (4.0) 1 (4.0) 0 5 (16.7) 5 (16.7) 2 (6.5) 4 (12.9) 6 (19.4) 0 3 (10.7) 3 (10.7) 0 3 (12.0) 3 (12.0) 0 1 (4.0) 1 (4.0) 0 2 (6.7) 2 (6.7) 0 3 (9.7) 3 (9.7) (4.0) 1 (4.0) (46.7) 14 (46.7) 1 (3.2) 12 (38.7) 13 (41.9) 1 (3.6) 2 (7.1) 3 (10.7) 0 8 (32.0) 8 (32.0) 0 4 (16.0) 4 (16.0) 0 3 (10.0) 3 (10.0) (8.0) 2 (8.0) ( ) : :
9 ( -308) N 95% 95% N 95% 95% N 95% 95% * ( %) * * (x (x (x BUN/Urea (mmol (mmol * (umol * (mmol LDH (mmol SGOT/ASAT SGPT/ALAT (umol *p0.05; van Elteren test 95% Half length ICU GOT N 95% 95% N 95% 95% N 95% 95% ( %) ( ( ( BUN/Urea (mmol (mmol (umol (mmol (mmol SGOT/ASAT * SGPT/ALAT (umol *p0.05; van Elteren test 95% Half length 590
10 / Part ( -310) Part Part Part N Q1Q3 N Q1Q3 N Q1Q3 N Q1Q3 N Q1Q3 N Q1Q3 90% 90% 90% 90% 90% 90% ( ) ( ) ( ) ( ) ( ) ( ) (g/dl) ( ) ( ) ( ) ( ) ( ) ( ) ( ( ) ( ) ( ) ( ) ( ) ( ) ( ( ) ( ) ( ) ( ) ( ) ( ) ( ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) (.81.62) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 591
11 Part Part Part N Q1Q3 N Q1Q3 N Q1Q3 N Q1Q3 N Q1Q3 N Q1Q3 90% 90% 90% 90% 90% 90% BUN/Urea mg/dl ( ) ( ) ( ) (0.34.6) ( ) ( ) mg/dl ( ) ( ) ( ) ( ) ( ) ( ) * mg/dl ( ) ( ) ( ) ( ) ( ) ( ) * mg/dl ( ) ( ) ( ) ( ) ( ) ( ) (g/dl) ( ) ( ) ( ) ( ) ( ) ( ) ALP (IU ( ) ( ) ( ) ( ) ( ) ( ) SGOT/ASAT (IU ( ) ( ) ( ) ( ) ( ) ( ) SGPT/ALAT (IU ( ) ( ) ( ) ( ) ( ) ( ) GTP (IU ( ) ( ) ( ) ( ) ( ) ( ) mg/dl ( ) ( ) ( ) ( ) ( ) ( ) (g/dl) ( ) ( ) ( ) ( ) ( ) ( ) Na (meq ( ) ( ) ( ) ( ) ( ) ( ) K (meq ( ) ( ) ( ) ( ) ( ) ( ) Cl (meq ( ) ( ) ( ) ( ) ( ) ( ) Ca (mg/dl) ( ) ( ) ( ) ( ) ( ) ( ) P (mg/dl) ( ) ( ) ( ) ( ) ( ) ( ) ph (5.96.6) ( ) (5.86.2) (0.20.8) (5.76.2) ( ) *p0.05; Part Wilcoxon ICU (W97-245W97-246) / (J-DEX ) 592
387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )
More information2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742
MJR-35 34 1 1 a MRICT b 2Beecham r-afs 3 4 20 4 mg/ 20 40 5 6 2 1 2 3 44 mg/ 5 6 7 8 4 Gn-RH 742 9 10 11 12 1 20 60 1 1MJR-351 mg/ 0.25 2 Lot. No. 2MJR-352 mg/ 1 1 Lot. No. 3MJR-354 mg/ 1 2 Lot. No. 2
More information(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
More information125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
More information2 129-B*-006P 129-B*-007P C*-004P 129-D*-001P ADH B*-006P B*-007P C*-004P D*-001P Na
2.7.4 2.7.4.1 2.7.4.1.1 11 ADH 1 ADH 1 4 7 129-A*-003 129-B*-001 129-E*-001P 129-G*-001 129-H*-002 129-H*-004 129-H*-005 132 242 4 129-B*-004 129-C*-005P 129-H*-003 129-H*-006 44 ADH ADH 129-C*-001P 16
More information21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty
More information001-029_”÷’X
54 2012 1 29 Kimori Daisuke Kamijo Takashi Takahashi Akira 1993 19951997 2001 10 1993 1999 1992 54 2012 1993 20 LDH BUNCRE UA CPK GOT CPK LDH UA CPK LDH UA CPK 1989 2001 2000 1989 1995 2003 2005 1989 54
More information高脂血症の検査
35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH
More information2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
More informationsick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
More informationSample2 g/dl Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl
( ) Sample2 g/dl 10 9 8 7 6 Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl 117 5.92 0.09 1.6 118 5.92 0.10 1.6 7 5.77 0.14 2.4 118 8.28 0.15 1.8 118 8.28 0.15 1.8 7 7.26 0.46 6.4 119 119 6.84 7.10 0.11 0.11
More informationデスフルラン
デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.
More informationuntitled
Metabolic syndrome,,,, 81 81 , 17 17 2 Lung Ca non small cell carcinoma / / food( food( ) drug( drug( ) 100mg 750mg WBC 5510/ l RBC 483 / l Hb 10.3g/dl, Ht 42.0% Plt 19.0 / l TP 8.1g/dl Alb 4.6g/dl Glb
More information日本呼吸器学会雑誌第47巻第6号
Fig.1 A,ChestX-rayfilm demonstratingatumorshadow intherightlowerlungfield.b,chestct scan demonstratingtherightmiddlelobemass,measuring9.0 7.3cm.C,AbdominalCT scanshowingfree airintheabdominalcavityanddirtyfatsignaroundthesigmoidcolontumor.
More informationレイアウト 1
1 1 3 5 25 41 51 57 109 2 4 Q1 A. 93% 62% 41% 6 7 8 Q1-(1) Q2 A. 24% 13% 52% Q3 Q3 A. 68% 64 Q3-(2) Q3-(1) 9 10 A. Q3-(1) 11 A. Q3-(2) 12 A. 64% Q4 A. 47% 47% Q5 QQ A. Q Q A. 13 QQ A. 14 Q5-(1) A. Q6
More information10_11p01(Ł\”ƒ)
q q q q q q q q q q q q q q q q q q q q q q q q q qq q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q
More information九州支部卒後研修会症例
血液検査研修会 ( 第 25 回 ) 検査の異常から探る! 造血器腫瘍へのアプローチ 症例提示 症例 1~8 - 症例発表者 - 症例 1 藤崎恵熊本医療センター 症例 2 荒木敏造浜の町病院 症例 3 古城剛鹿児島大学病院 症例 4 佐々木高太郎都城健康サービスセンター 症例 5 矢田佳愛 大分県立病院 症例 6 下田博臣 健康保険諫早総合病院 症例 7 堤陽子 佐賀県医療センター好生館 症例 8
More information日本呼吸器学会雑誌第44巻第10号
β Table1 Laboratoryfindingsonthefirstvisit Hematology WBC Neut. Lyn. Mon. Eos. Bas. RBC Hb Ht Plate 5,650 /μl 79.2 % 14.9 % 3.9 % 1.8 % 0.2 % 418 10 4 /μl 12.5g/dl 38.4 % 21.2 10 4 /μl Serology CRP IgG
More information血糖高いのは朝食後のため検査項目 下限値上限値 単位名称 9 月 3 日 9 月 6 日 9 月 15 日 9 月 18 日 9 月 21 日 9 月 24 日 9 月 28 日 10 月 1 日 10 月 3 日 10 月 5 日 10 月 9 日 10 月 12 日 10 月 15 日 10 月
検査項目 下限値上限値 単位名称 7 月 9 日 7 月 10 日 7 月 11 日 7 月 12 日 7 月 13 日 7 月 17 日 7 月 20 日 7 月 23 日 7 月 25 日 7 月 27 日 7 月 30 日 8 月 3 日 8 月 6 日 8 月 8 日 8 月 10 日 8 月 12 日 8 月 15 日 8 月 17 日 8 月 20 日 8 月 22 日 8 月 24 日
More informationBUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
More information_02三浦.indd
36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut
More information取扱説明書 [F-05E]
F-05E 12.11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 a b 22 c d e 23 24 a o c d a b p q b o r s e f h i j k l m g f n a b c d e f g h 25 i j k l m n o p q r s a X b SD 26 27 28 X 29 a b c
More information日本呼吸器学会雑誌第48巻第6号
Fig.1 Cutaneousfindingsandpathologicalfindingsofatransbronchiallungbiopsy(TBLB)andlichenifiedeczemaoftherightforearm.Thepatienthadlichenifiedeczemaonhisextremitiesandbodytrunk (1a:rightforearm,1b:leftthigh).Therewasinfiltrationoftheinflammatorylymphocytes,edemaandabrasioninthetype2alveolarepithelium
More information37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
More information温泉の化学 1
H O 1,003 516 149 124 2,237 1974 90 110 1km 2,400 ( 100 Mg 200 (98 ) 43,665 mg 38,695 mg 19,000 mg 2000 2000 Na-Ca-Cl 806 1970 1989 10 1991 4 ph 1 981 10,000 1993... (^^; (SO_4^{2-}) " " 1973-1987 1970
More informationコロイド化学と界面化学
x 25 1 kg 1 kg = 1 l mmol dm -3 ----- 1000 mg CO 2 -------------------------------------250 mg Li + --------------------------------1 mg Sr 2+ -------------------- 10
More information72 20 Ope / class Alb g/ cm 47.9kg : /min 112/60m
72 20Ope 68 69 2006 4 50 20 / 52 2006 4 1 2006 4 4 24 class 699.4 5 2 5 23 6 6 15 6 19 6 16 Alb2.03+ 7.5g/ 6 21 153.5cm 47.9kg : 36.7 89/min112/60mmHg (-) (-)S1 S2 S3(-) S4(-) - - 6 15 (+) TP4.9g/dl Alb2.0g/
More information日本呼吸器学会雑誌第44巻第1号
β β l β β Table1 Laboratorydataonadmission Hematology WBC 9,910/μl neut 72.4% lym 20.2% eos 0.9% mon 6.1% baso 0.4% RBC 491 10 4 /μl Hb 16.8g/dl Ht 48.3% PLT 29.8 10 4 /μl ESR 3mm/hr Biochemistry TP Alb
More information2 章 +αの 情 報 に 着 目 する! 1 血 球 算 定 検 査 結 果 2 生 化 学 検 査 結 果 手 がかりに 乏 しいのも+α 1 症 例 をみてみよう! 1 60 吉 見 祐 輔 1 2 11percutaneous coronary intervention PCI104 38.
2 章 +αの 情 報 に 着 目 する! 1 血 球 算 定 検 査 結 果 2 生 化 学 検 査 結 果 手 がかりに 乏 しいのも+α 1 症 例 をみてみよう! 1 60 吉 見 祐 輔 1 2 11percutaneous coronary intervention PCI104 38.1 130 75mmHg 83 16 SpO 297 1 3 WBCL RBC10 4 L Hb g
More information<8C9F8DB85F3338E4508CB495612E786C73>
尿 検 査 初 回 登 録 前 回 調 査 時 から 変 更 なし 追 加 データあり 随 時 尿 蛋 白 ( 定 性 ) - - - 糖 ( 定 性 ) - - - 潜 血 ( 定 性 ) - - - 項 目 に が 付 与 されている 場 合 : 該 当 の 項 目 は 1/5 尿 検 査 血 球 算 定 初 回 登 録 前 回 調 査 時 から 変 更 なし 追 加 データあり WBC ( )
More informationVOL.39 S-3
VOL.39 S-3 CHEMOTHERAPY SEPT.1991 Table 1. Background of characteristics and allocation of 5 healthy male volunteers in a multiple-dose study on panipenem/betamipron Day 1 Fig. 1. Schedule of multiple-dose
More informationCD1 data
測定方法 ( ラット マウス共通 一部の系統でのみ測定されている項目も含む ) 血液学的検査 測定条件 絶食 : 約 16 時間 麻酔 : ネンブタール腹腔内投与 採血部位 : 後大静脈 抗凝固剤 :EDTA-2Na(WBC RBC HGB HCT MCV MCH MCHC PLT) EDTA-2K( 網状赤血球 白血球百分比検査 ) クエン酸 Na( 凝固系検査 ) 測定機器 : セルタック α(
More information無印良品のスキンケア
2 3 4 5 P.22 P.10 P.18 P.14 P.24 Na 6 7 P.10 P.22 P.14 P.18 P.24 8 9 1701172 1,400 1701189 1,000 1081267 1,600 1701257 2,600 1125923 450 1081250 1,800 1125916 650 1081144 1,800 1081229 1,500 Na 1701240
More informationCompuSec SW Ver.5.2 アプリケーションガイド(一部抜粋)
64 PART 9 65 66 PART10 67 1 2 3 68 PART 10 4 5 69 1 2 3 4 5 70 PART 10 6 7 8 6 9 71 PART11 72 PART 11 1 2 3 73 4 5 6 74 PART 11 7 8 9 75 PART12 76 PART 12 1 2 3 4 1 2 3 4 77 1 2 3 4 5 6 7 8 78 PART13 79
More information65歳雇用時代の賃金制度のつくり方
1 65 2005 2 65 18 65 2 PART 165 6 7 8 11 14 16 60 17 25 PART 2 28 35 () 10 35 () 35 () 36 () 39 () 39 () 41 () 42 () 42 () 44 (10) 44 (11) 47 1 15 2007 2 35 3 10 10 2.5 2.5 1.5 0.5 2.5 2.5 1.5 0.5 10
More information<4D F736F F D F8DCC97918C7B82CC8C8C897490B689BB8A AB8FF382CC908488DA2E646F63>
1 8 4 26 2 ( )(0 20 )(21 64 ) 4 (TP) (GOT GPT) (ALP)(LDH) (Amyl)(CPK) (T cho) (TG) (NEFA) HDL (HDL c) (Na) (K) (cl) (Ca)(P) (Crea)(UA) (Glu) 19 TP GOT LDH T cho NEFA.HDL c K UA GPT LDH CPK T cho TG NEFA
More information50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
More information1 c H O. H C C O H. CH 3 COOH ( ). C 2 H 4 O 2. CH 2 O H [. CH2 CH 2 CH CH ]. CH 3 COOH 3 1 C H ( ) CH 3 CH 3 CH CH CH
1.. 3 (). 2 4 2. 2 [. 2 2 ]. 3 3 1 () 3 3 2 3 ( 3 ) 2 ( 3 ) 2 2,., (). (, ).,.,.. 3 3 3 3 ( ). 1. 2. N 2 2 N 3 ( ) ( ) N N ( N ) N N ( N ) N N 2 N 2 S 3 N N = N [...,. ] 2 1 1 4 ( 6 ) ( 1 ). 2 ( 4 ) (
More information日本呼吸器学会雑誌第44巻第7号
Table1Laboratoryfindingsonadmission Hematology Serology LungFunctionTest WBC 7,410 /μl CRP 7.7mg/dl VC 3.12L(97.2%) Neut 66.4 % KL-6 777U/ml FEV1.0 2.35L(78.25%) Eosino 3.2 % PT (INR) 0.94 %DLCO 47.6 %
More information1総説_諸疾患における亜鉛測定の意義.indd
O 43,000 C 16,000 H 7,000 N 1,700 Ca 1,160 P 670 K 150 S 112 Cl 85 Na 63 Mg 25 70 100 3 5mg 15 mg 0.5 0.1 mg 0.1 3.0 mg 0.5 1.0 mg 1.0 5.0 mg -P B 12 0.01 0.06 mg 0.02 0.2 mg 0.01 0.04 mg 0.02 0.2 mg 0.1
More informationA9RF112.tmp.pdf
9 1-1 9 9 10 11 13 17 1-2 18 18 19 20 21 21 22 23 24 26 2-1 26 26 26 30 33 35 2-2 36 36 38 40 44 44 45 3-1 45 45 47 49 51 53 58 3-2 59 59 60 62 64 68 69 70 4-1 70 70 72 4-2 73 73 74 74 75 76 77 77 79 80
More information1 8 ぜ 表2 入院時検査成績 2 諺齢 APTT ALP 1471U I Fib 274 LDH 2971U 1 AT3 FDP alb 4 2 BUN 16 Cr K4 O Cl g dl O DLST 許 皇磯 二 図1 入院時胸骨骨髄像 低形成で 異常細胞は認め
1 8 ぜ 表2 入院時検査成績 2 諺齢 APTT ALP 1471U I Fib 274 LDH 2971U 1 AT3 FDP 125 6 7 alb 4 2 BUN 16 Cr K4 O Cl g dl O 7 137 DLST 許 皇磯 二 図1 入院時胸骨骨髄像 低形成で 異常細胞は認められない PAIgG 177 3ng 107 cell meq 1 砂糖水試験 一 Fe 236 μg
More information日赤 No.35☆/7.河相
2 64 2 Mucosa-Associated Lymphoid TissueMALT T γ- 1 Key words T 1 2 64 47 54 60 MALT 63 T MALT 6062-8 63 1 T MALT 63 CHOP 2 35 28 30 28 75 μg 200 mg 20 mg 200 mg 400 mg/80 mg 2 35 mg 1 2 150 mg 200 mg
More information/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg
17 2005/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 32 5/8 36.1 :90 /:114/64 mmhg 166.2 cm64.3 kg 3.9 g/dl 1.6 g/dl 382 mg/dl 408 mg/dl
More information物理化学I-第12回(13).ppt
I- 12-1 11 11.1 2Mg(s) + O 2 (g) 2MgO(s) [Mg 2+ O 2 ] Zn(s) + Cu 2+ (aq) Zn 2+ (aq) + Cu(s) - 2Mg(s) 2Mg 2+ (s) + 4e +) O 2 (g) + 4e 2O 2 (s) 2Mg(s) + O 2 (g) 2MgO(s) Zn(s) Zn 2+ (aq) + 2e +) Cu 2+ (aq)
More informationuntitled
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -
More informationWBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH
54 2002 3 1992 2002 3 2002 7 2004 1 15 4Kg74.0Kg 1 24 80.6 kg BUN 26.0mg/dl, s-cr 2.3mg/dl, 3+ 1 27 40 /34 174.3 cm 80.6 kg 1 10kg36.8 120/70 mmhg 88 / 14 / fibrinogen 616 mg/dl, TP 3.6 g/dl, Alb 1.4 g/dl,
More informationICU ( ) ICU ( ) ICU SpO 2 ICU ( ) -297 S.E DEX: N=30 DEX: N= 6 (J-DEX Placebo: N=30 Placebo: N= 3 65 DEX: N=16 DEX: N= 3 Placebo: N=
ICU ( ICU ( ICU SpO 2 ICU ( -297 S.E. -75-94 65 DEX: N=30 DEX: N= 6 ( Placebo: N=30 Placebo: N= 3 65 DEX: N=16 DEX: N= 3 Placebo: N=19 Placebo: N= 4 65 DEX: N=53 DEX: N=42 DEX: N=21 DEX: N=10 ( Placebo:
More information_03大山.indd
36, 13-19, 2016 2 24 24 6 12 1% 1 DIC 2 1 40 30 0 0 IVM - ICSI - ; in vitro mturtion - intrcytoplsmic sperm injection 32 5 mm 37 3 1,300 g 7 H 10.1 g/dl 10 ER 104/69 mmhg 78 / 1 FBG 1 100 ml FFP 300 ml
More information1
1 1 2 3 4 5 6 7 8 9 10 11 Q7 3 0.0 10.0 20.0 30.0 40.0 50.0 18-29 30-39 40-49 12 Q8 Q7 0 20 40 60 23 23 13 14 15 16 Q10 3 0.0 20.0 40.0 60.0 80.0 18-29 30-39 40-49 17 18 Q12 3 0.0 10.0 20.0 30.0 40.0 18-29
More informationuntitled
NPO 2006( ) 11 14 ( ) (2006/12/3) 1 50% % - - (CO+H2) ( ) 6 44 1) --- 2) ( CO H2 ) 2 3 3 90 3 3 2 3 2004 ( ) 1 1 4 1 20% 5 ( ) ( ) 2 6 MAWERA ) MAWERA ( ) ( ) 7 6MW -- 175kW 8 ( ) 900 10 2 2 2 9 -- - 10
More information/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1
11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1
More information当院の血液検査室の概要 血液検査 system 自動血球分析装置塗抹標本作製装置 La-vietal LS (Sysmex 社 ) XN-3000 (Sysmex 社 ) XN 台 ( RET WPC PLT-F の各チャンネル ) XN 台 SP-10 (Sysmex
いまさら聞けないシリーズ CBC スキャッタから目視血液像を追加するポイント 済生会習志野病院検査科深海律子 当院の血液検査室の概要 血液検査 system 自動血球分析装置塗抹標本作製装置 La-vietal LS (Sysmex 社 ) XN-3000 (Sysmex 社 ) XN-2000 1 台 ( RET WPC PLT-F の各チャンネル ) XN-1000 1 台 SP-10 (Sysmex
More information京都盆地の地下水
28 1 29 8km 20km [1] [2-4] 1993 [5] [1] 1980 22(4) pp.8-22 [2] 1929 6 pp.568-588 [3] 1984 No.23 pp.1-100 [4] 1992 45(1) pp.54-62 [5] 1933 8(9) pp.417-430 20 km 8km 0.7 km 125 km 3 25 m 300 700 m 56 44
More informationMicrosoft Word - 高橋_国試講習会2006m.doc
2006 19 150 20 200 19 80 2 70 1 45 1 1 30 20 105 2 40 1 1 31 95 2 25 1 1 32 1. 2. 3. 4. 5. 1 [] 25 12.5% 2006/3 6 2 1 2 3 7 A a b c d 11 e B a b c d C a b c D a b E a b c d 2 15 16 17 18 19 20 2001 2002
More information頸部リンパ節腫張 のコピー.pptx
17 1cm LMP General : BP110/70 HR60 RR16 T37.2 Eye Oral Neck ( cm Lungs Heart Abd Skin : cm Hb g/dl Ht Plt. /µl WBC /µl Seg Lym Mono AT-Ly Baso Na meq/l K meq/l Cl meq/ L Ca BUN mg/dl Cr mg/ dl GOT IU/L
More information取扱説明書 [F-06E]
F-06E 3.6 2 3 4 5 6 7 8 9 0 2 3 4 5 6 a b c d a b c d 7 a b cd e a b c 8 d e 9 20 a b b a a b 2 22 b a c 23 d 24 a b c d e f g h l m n o p i j k ku v w q r s t x y a b c d e f g h i j k l m n o p q
More informationHOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly
HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 S S S Phe Val Asn Gln His Leu Cys Gly Ser His Leu
More information- 9 91, (2006)
Case study level Ma Management of testicular cancer - 9 91, 10 0.7 2.4 (2006) 20 30 20 20-40 AFP -hcg -hcg AFP TNM T ptx pt0 ptis pt1 / pt2 / pt3 / pt4 / N NX N0 N1 2cm 1 2cm N2 2cm 5cm 1 5cm N3 5cm TNM
More information近畿中国四国農業研究センター研究報告 第7号
230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15
More information21 70.9 22 62.9 22 90 80 60 40 23 58 17 42 31 77.5 9 22.5 1 n 40 40 0 2 2 5.0 50 0 3 3 7.5 60 3 12 15 37.5 70 12 5 17 42.5 80 1 1 2 5.0 90 1 0 1 2.5 4
462015 Nagoya community school for health Think health scientifically : the life style and the health condition of seminar participants Hisae USAMI 21 36 67 1/3 21 21 21 1 23 6 68.2 91 43 70 42.56037.5
More information1996 papilloma virus 2001 Bowen AIHA PSL1mg/kg BMA PRCA parvovirus B19 PVB19 DNA PCR PV IgM 4 PVB19 PRCA MAP PVB19 DNA DNA PR
1996 papilloma virus 2001 Bowen2002 12 2003 2 2002 9 10 AIHA PSL1mg/kg BMAPRCA parvovirus B19 PVB19 DNA PCR PV IgM 4PVB19 PRCA MAPPVB19DNA DNA PRCA IVIG;20 50g/ IVIG PVB19AIHA steroid 15 20mg/day 2003
More information測定方法 測定方法 ( ラット マウス共通 一部の系統でのみ測定されている項目も含む ) 血液学的検査 測定条件 絶食 : 約 16 時間 麻酔 : ネンブタール腹腔内投与 採血部位 : 後大静脈 抗凝固剤 : EDTA-2Na(WBC RBC HGB HCT MCV MCH MCHC PLT) E
測定方法 測定方法 ( ラット マウス共通 一部の系統でのみ測定されている項目も含む ) 血液学的検査 測定条件 絶食 : 約 16 時間 麻酔 : ネンブタール腹腔内投与 採血部位 : 後大静脈 抗凝固剤 : EDTA-2Na(WBC RBC HGB HCT MCV MCH MCHC PLT) EDTA-2K( 網状赤血球 白血球百分比検査 ) 3.2% クエン酸 Na( 凝固系検査 ) 測定機器
More information1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61
1 2 2 ANCApouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - '03 2 3 31 UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, 3+ 4 14 156.0 cm 61.5 kg 36.9 158/92 mmhg 90 1. ANCA 2. 3. IgG4 deposit
More information1) Urlne analysls 7)Serologlcal exam. 1 1)ECG W.N.L. sugar 0% CRP (-) urobillnogen N(+) RA (+) 12)Renal function albumin 3(+) ASLO (-) PSP test 15' 40
A case of membranoproliferative glomerulonephritis accompanied with hyper IgM immunodeficiency Kenichiro SHIGEMOTO, Koji WADA, Naoki HAMAGUCHI, Akira HIRABAYASHI, Shunji TOI, Koji USUI, Michiko ARITA,
More informationindd
18 61 1 2011 症例報告 2010 5 13 2010 12 20 A Case of Varicella with Severe Back Pain in a Patient with Systemic Lupus Erythematosus RIE SAITO, KIORI YANO, FUMIKO KATSUSHIMA, HARUYO IWADATE, HIROKO KOBAYASHI,
More informationC033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
More informationph
14 12 9 3 4 1 7 1.1..................... 7 1.2 ph............................ 9 1.2.1...... 9 1.2.2.... 12 4.4..... 55 1.2.3 14 4.4.1......... 56 1.2.4............. 19 2 21 2.1.......... 21 2.2......................
More information02.O...r.A..
8 300ha k (m 3 / / ) (0 2 ) 0405 135 270 2 12 0540 162 351 12 24 0810 216 486 500kg 135 459 127 1987 (m 3 / / ) 0566 2266 5947 9 18kg 0057 0425 1019 18 45 0142 0566 1358 45 675 0198 0708 2038 675 945 0283
More informationケイセントラ_製品情報概要_H1-4_収載_新発売
DIC 135-627 12 CONTENTS 34 32 33 1 2 K 34 3 4 5 12 12 18 24 3 31 31 31 33 KVKA K K VKA VKA K - PT-INR KC S 1996VKA VKA 3 KK CS 33 34 35 35 35 36 36 K 32 33 213 4VKA 12VKAFDA Kcentra 42 217 1 in vitro 1
More informationC VECS C F M kg A E W kg I A R. R. Gkg MGD MGD MGD MGD SPKMGD MGD MGD SPK SPK MGD MMP MMP MMP kg mmhg Intrascleral prosthesis : ISPISP ISP ISP ISP ISP ISP ISP ISP ISP mm mm ISP mm min mm min ISP mm min
More information2 Zn Zn + MnO 2 () 2 O 2 2 H2 O + O 2 O 2 MnO 2 2 KClO 3 2 KCl + 3 O 2 O 3 or 3 O 2 2 O 3 N 2 () NH 4 NO 2 2 O + N 2 ( ) MnO HCl Mn O + CaCl(ClO
1 [1]. Zn + 2 H + Zn 2+,. K Ca Na Mg Al Zn Fe Ni Sn Pb H Cu Hg Ag Pt Au H (H + ),,. [2] ( ) ( ) CO 2, S, SO 2, NH 3 () + () () + () FeS Fe S ( ) + ( ) ( ) + ( ) 2 NH 4 Cl + Ca(OH) 2 Ca O + 2 NH 3,.,,.,,.,.
More information参考資料5 農薬評価書 メタアルデヒド(食品安全委員会資料)
1 3 3 4 5. 6 1. 6 2. 6 3. 6 4. 6 5. 6 6. 6 7. 6. 7 1. 7 2. 8 (1) 8 (2) 9 (3) 9 (4) 10 (5) 10 3. 11 (1) 11 (2) 11 (3) 11 (4) 12 4. 12 (1) 12 (2) 12 (3) 13 5. 13 6. 13 7. 14 8. 15 9. 16 10. 16 (1) 90 16-1
More informationindd
60 4 2010 197 症例報告 1 1 1 2 2 2 2 3 4 1 2 3 4 2010 7 27 2010 9 24 Case of a Young Adult Male Complicated with Ischemic Colitis EMI OGATA 1, TAKERU WAKATSUKI 1, HIROAKI SAKAMOTO 1, NATSUMI SAKAMOTO 2, OSAMU
More information5 CSF 6 CSF 7 CSF CSF CDV CDV GFAP CSF Pandy test NSE MBP LDH mu/ml 0-5 /µl AST mu/ml CK mu/ml <25 mg/dl<45 mg/dl GLU
CT MRI CSFCSF CSF CSF CSF CSF CSF (cisternal puncture) CSF 20-23G 90 (20-23G) : CSF
More information第4次酸性雨全国調査報告書(平成16年度) -(Ⅱ)付表編-
1.12.24 P. 5.4.3.1 NO NOP. 5.4.3.2P. 5.4.3.3 P. 5.4.3.4 P. 2.18 2.19 P. 2.20 P. 2.21 P. P. 5.5.2.11 SOA P. 5.5.2.12 NO B A B 1.1 16 mm FRS Vol. 31 42006 1.2 ph 16 FRS ms/m FRS 1.3 16 Vol. 31 42006 μmol/l
More information44-2目次.indd
Bull. of Nippon Sport Sci. Univ. 44 (2) 95 101 2015 1) 2) 1) III 2) An investigation of the validity of hemoglobin monitoring apparatus in collegiate EKIDEN runner s conditioning management Inkwan HWANG
More information